Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Gasterol Intestinal Symposium
Everolimus Has Minimal Economic Impact on Treatment of Pancreatic NETs
By
Caroline Helwick
Gasterol Intestinal Symposium
March 2012, Vol 3, No 2
San Francisco, CA—Using a prediction model to analyze the impact of adding targeted agents to the treatment of pancreatic neuroendocrine tumors (pNETs), everolimus (Afinitor) had a minimal overall impact on healthcare expenditures, by reducing infusions and surgical procedures costs, according to a study presented at the 2012 Gastrointestinal Cancers Symposium.
Read Article
For Pancreatic Cancer, Neoadjuvant Chemoradiation Cost-Effective Compared with Surgery First
By
Caroline Helwick
Gasterol Intestinal Symposium
March 2012, Vol 3, No 2
San Francisco, CA—For resectable pancreatic cancer, administering chemo - therapy and radiation before surgery results in better outcomes and lower costs than performing surgery first, reported researchers from M.D. Anderson Cancer Center, Houston.
Read Article
Oncotype DX Assay Changes 29% of Treatment Decisions in Patients with Stage II Colon Cancer
Gasterol Intestinal Symposium
March 2012, Vol 3, No 2
San Francisco, CA—Results obtained on the Onco
type
DX Colon Cancer Assay led to changes in treatment decisions 29% of the time for patients with stage II colon cancer, according to a survey of community oncologists reported at the 2012 Gastrointestinal Cancers Symposium.
Read Article
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma